The 5,6-dichloro-1-β-d-ribofuranosylbenzimidazole (RBD), a reversible transcriptional elongation inhibitor, was used to treat GTF2F2 overexpression/knockdown PCa cells (Fig. S9A, B) for 3 h, and RNA was collected at different time points for qRT-PCR analysis to detect the level of the pre-mRNA. The gene discussed is GTF2F2; the disease is posterior cortical atrophy.